EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

MAP17 Orchestrates SGLT2-Dependent Glycolytic Reprogramming to Drive Trained Immunity and Accelerate Atherosclerosis

Jianjin Wu, Lei Wang, Fukang Zou iD, Fangbing Liu, Guanyu Fang, Kai Cheng iD, Haochen Gao iD, Kangkang Zhi iD, Lefeng Qu iD

Arteriosclerosis, Thrombosis, and Vascular Biology · 2026

DOI: 10.1161/atvbaha.126.324585 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Arteriosclerosis, Thrombosis, and Vascular Biology, 2026. Verfasst von Jianjin Wu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Vascular and Endovascular Surgery (J.W., F.Z., F.L., G.F., K.C., K.Z., L.Q.), Second Affiliated Hospital of Naval Medical University, S…. Hauptthemen laut MEDLINE: Glycolysis, Trained Immunity, Macrophages, Atherosclerosis. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Atherosclerosis is driven by metabolic-immune crosstalk, in which trained immunity sustains vascular inflammation. MAP17 (membrane-associated protein 17), a redox- and metabolism-regulating adaptor protein, functions as a potential upstream driver of SGLT2 (sodium-glucose cotransporter 2). We aimed to determine whether MAP17 links hyperglycemia to glycolytic activation, inflammatory polarization, and plaque progression in atherosclerosis. METHODS: MAP17 expression and its correlations with clinical risk factors were analyzed in serum from 30 patients with atherosclerosis. A trained immunity model was established in bone marrow–derived macrophages via sustained high glucose and IFN-γ (interferon-γ)/lipopolysaccharide stimulation. Functional assays were performed after MAP17 overexpression/knockdown, SGLT2 silencing, or glycolysis inhibition. RESULTS: MAP17 was significantly coupregulated in patients with atherosclerosis, with the highest levels observed in those with concomitant diabetes or metabolic syndrome, and closely associated with elevated proinflammatory M1-like cytokines. Immunohistochemistry of carotid plaques confirmed its colocalization with SGLT2 within CD68 + macrophage-rich, lipid-laden, and inflamed regions. In bone marrow–derived macrophages, high glucose robustly induced MAP17 expression, which unidirectionally upregulated SGLT2, enhanced glycolytic flux, increased lactate production, and promoted M1-like polarization and foam cell formation. MAP17 knockdown markedly suppressed SGLT2 expression, glycolysis, and TNF-α (tumor necrosis factor-α)/IL (interleukin)-1β secretion, whereas MAP17 overexpression restored glycolytic activity, proinflammatory phenotype, and foam cell generation even in SGLT2-deficient cells. In diabetic chimeric Apoe −/− mice, MAP17 activation correlated with increased glycolytic marker expression, higher proinflammatory M1-like macrophage ratios, aggravated vascular inflammation, and greater plaque burden; these effects were mitigated by MAP17 or SGLT2 silencing, or by glycolysis inhibition. CONCLUSIONS: MAP17 is a key upstream controller of the SGLT2-glycolysis axis that promotes trained immunity and accelerates atherosclerosis. Targeting MAP17 may disrupt the metabolic-inflammatory feedback loop and represents a promising therapeutic strategy for diabetic atherosclerosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlycolysisTrained ImmunityMacrophagesAtherosclerosisSodium-Glucose Transporter 2Carotid Artery DiseasesAnimalsHumansMaleMice, Inbred C57BLPlaque, AtheroscleroticCells, CulturedFemaleDisease Models, AnimalMetabolic ReprogrammingSignal TransductionInflammation MediatorsMiceMice, Knockout, ApoEMice, Knockout

Stichwörter der Autor:innen

atherosclerosisglycolysisoxidative stressreactive oxygen speciestrained immunity

Substanzen

Sodium-Glucose Transporter 2SLC5A2 protein, humanInflammation Mediators

Autor:innen und Institutionen

  • Department of Vascular and Endovascular Surgery (J.W., F.Z., F.L., G.F., K.C., K.Z., L.Q.), Second Affiliated Hospital of Naval Medical University, Shanghai, China.
  • Department of Vascular Surgery, First Affiliated Hospital of Dalian Medical University, China (L.W.).
  • Department of Stomatology (H.G.), Second Affiliated Hospital of Naval Medical University, Shanghai, China.

ORCID-Profile: Fukang Zou, Kai Cheng, Haochen Gao, Kangkang Zhi, Lefeng Qu

Zitieren

APA

Wu, J., Wang, L., Zou, F., Liu, F., Fang, G., Cheng, K., Gao, H., Zhi, K., & Qu, L. (2026). MAP17 Orchestrates SGLT2-Dependent Glycolytic Reprogramming to Drive Trained Immunity and Accelerate Atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology. https://doi.org/10.1161/atvbaha.126.324585

Vancouver

Wu J, Wang L, Zou F, Liu F, Fang G, Cheng K, et al. MAP17 Orchestrates SGLT2-Dependent Glycolytic Reprogramming to Drive Trained Immunity and Accelerate Atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology. 2026. doi:10.1161/atvbaha.126.324585

BibTeX
@article{Wu2026,
  author = {Wu, Jianjin and Wang, Lei and Zou, Fukang and Liu, Fangbing and Fang, Guanyu and Cheng, Kai and Gao, Haochen and Zhi, Kangkang and Qu, Lefeng},
  title = {MAP17 Orchestrates SGLT2-Dependent Glycolytic Reprogramming to Drive Trained Immunity and Accelerate Atherosclerosis},
  journal = {Arteriosclerosis, Thrombosis, and Vascular Biology},
  year = {2026},
  doi = {10.1161/atvbaha.126.324585}
}
Kostenlos starten →